Picture of wind turbine against blue sky

Open Access research with a real impact...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs.

The Energy Systems Research Unit (ESRU) within Strathclyde's Department of Mechanical and Aerospace Engineering is producing Open Access research that can help society deploy and optimise renewable energy systems, such as wind turbine technology.

Explore wind turbine research in Strathprints

Explore all of Strathclyde's Open Access research content

Use of slow release starch (SRS) to treat hypoglycaemia in type 1 diabetics

Qi, E. and Band, M. and Tester, R.F. and Piggott, J.R. and Hurel, S. (2010) Use of slow release starch (SRS) to treat hypoglycaemia in type 1 diabetics. Nutrition and Food Science, 40 (2). pp. 228-234. ISSN 0034-6659

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

The purpose of this paper is to evaluate if slow release starch (SRS) could be used to control/limit hypoglycaemia in type 1 diabetics. Ten type-1 diabetic volunteers were fitted with continuous glucose monitors for two periods of 3 days when undertaking their normal routine or when consuming 60?g SRS before sleep. The average number of nocturnal hypoglycaemic episodes where no SRS was consumed over 3 days was 2.7?±?2.0 but only 0.7?±?1.1 after SRS consumption before sleep. The duration of these events was equivalent to 318?±?282 and 140?±?337?min, respectively. Average nocturnal blood glucose concentration was 7.9?±?1.4?mmol?l-1 without SRS consumption but increased to 9.7?±?2.7?mmol?l-1 when SRS was consumed. These data were highly significant when subjected to analysis of variance (ANOVA) test on a subject by subject basis. The SRS may be used as a cost effective therapy to avoid hypoglycaemia in patients with type-1 diabetes. This paper reports for the first time the use of a physically modified waxy maize starch (SRS) to prevent/limit the incidence of nocturnal hypoglycaemia in type 1 diabetics.